Navigation Links
AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
Date:11/19/2009

VIENNA, Austria, November 19 /PRNewswire/ -- AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point. Furthermore, based on this analysis, the AD02 patients from the completed Phase I study will now be offered an AD02 booster vaccination.

AFFiRiS AG announced today, that Alzheimer's vaccine candidate AFFITOPE AD02 will undergo immediate tests for potential efficacy in a Phase II trial. This means that the company can focus its diversified development program for Alzheimer's vaccines earlier than initially planned. The reason for the decision is based on the interim analysis of the preceding Phase I testing.

Dr. Walter Schmidt, CEO and co-founder of the company, explains the company's surprisingly rapid decision: "Both vaccines AD01 and AD02 met the primary phase I endpoints demonstrating safety and tolerability and therefore both qualified for phase II testing. However, as a small biotech with a strong focus on optimized resourcing, we are always keen to prioritize. Based on the first interim analysis of secondary endpoints, which is confidential at this stage, we decided to focus in the first instance on AD02. The Phase II trial will start as early as possible, hopefully early next year."

Dr. Frank Mattner, CSO and co-founder, adds: "It is part of our strategy in the early phase of vaccine development to focus on more than one candidate, if possible. In this way, we diversify our risk. Based on this, we can then back in the first instance the potentially most promising candidate and put the others on
'/>"/>

SOURCE AFFiRiS AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
2. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
3. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
4. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
5. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
6. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
7. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009
8. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
9. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
10. Bavarian Nordic A/S - Half Year Interim Report 2009
11. Arpida Reports Interim Results For Six Months to 30 June 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 CORD:USE Cord Blood ... announce that it has entered into an Equity and ... which has licensed a series of patented technologies for the ... possible clinical applications.  Tianhe is performing Phase I/II clinical ... Spain using Tianhe,s Stem Cell Educator ...
(Date:9/30/2014)... Basel, Switzerland (PRWEB) September 30, 2014 ... advanced software solutions for drug discovery and ... the FUNGITECT consortium has chosen Genedata Selector ... next-generation sequencing (NGS) data. FUNGITECT is a ... of invasive fungal diseases via individualized anti-fungal ...
(Date:9/30/2014)... CORALVILLE, Iowa , Sept. 30, 2014 /PRNewswire/ ... in the discovery and development of proprietary new ... United States Patent and Trademark Office (USPTO) issued ... patent application entitled, "Benzoic Acid, Benzoic Acid Derivatives ... Methods of Making and Use Thereof." ...
(Date:9/30/2014)... DEL MAR, Calif. , Sept. 30, 2014 /PRNewswire/ ... devices for women,s health announces its receipt of a ... The FemmyCycle menstrual cup has also received FDA clearance ... Health Canada, and the CE in Europe. This patent is ... design. In conjunction with this issuance, the company is releasing ...
Breaking Biology Technology:CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2The FemmyCycle 2
... The Board of Directors of Schering-Plough Corporation (NYSE: SGP ... share. Payment will be made on Aug. 31, 2009, to ... 2009. As of March 31, 2009, there were 1,628,335,093 common ... also declared a quarterly dividend of $3.75 per share on the ...
... BASEL, Switzerland, June 23 Syngenta announced today the successful ... year maturity. The proceeds of the bond will be used ... said: "We have taken advantage of favorable current borrowing conditions ... bond issue is part of our normal funding requirements and ...
... SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials ... products, announced today that the company was recently nominated ... in pediatrics. The company is among three ... device analysts in recognition of the development of REPEL-CV(TM) ...
Cached Biology Technology:Syngenta Issues EUR 500 Million Eurobond 2SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination 2
(Date:9/30/2014)... hope: A new research report published in October 2014 ... explains how scientists developed a synthetic version of a ... in human and mouse eggs similar to the natural ... fertilization. , "We believe that the results of this ... of human fertilization by providing a precise answer to ...
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
(Date:9/29/2014)... of gut bacteria called Clostridium ramosum , coupled with ... work is published this week in mBio , the ... , A research team from the German Institute of Human ... bacteria including C. ramosum gained weight when fed ... ramosum were less obese even when consuming a high-fat ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2
... microscope integrates two Finnish innovations and brings new dimensions ... for Molecular Medicine Finland (FIMM) have in collaboration with ... finger gesture controlled microscope. The method is a combination ... multitouch display. The result is an entirely new ...
... Congress on Osteoporosis & Osteoarthritis in Valencia, Spain, Professor ... Pierre D. Delmas Prize. The prestigious award, ... Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International ... an individual who has made outstanding and major scientific ...
... - A lot of chatter goes on inside each one ... ears. Researchers at McMaster University discovered that the "cross-talk" ... important role in the development of psychiatric illness, intestinal diseases ... "The wave of the future is full of opportunity as ...
Cached Biology News:Big size multitouch display turned into a microscope 2ESCEO-IOF Servier Pierre D. Delmas Prize awarded to John. A. Kanis 2'Knowing it in your gut' is real 2
...
TNM-FH Insect Medium 1 liter...
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
Biology Products: